US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. Leqembi is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).

Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

Stockholm, Sweden October 31, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give increased patient benefit for patients with early Alzheimer’s disease, expanding approximately 1 point on CDR-SB compared to the ADNI[1]-population, with maintained safety profile. In addition, data show that 46% of patients who had low levels of brain

Leqembi® revenue totaled JPY 10 billion in the third quarter 2024

Stockholm, Sweden, October 30, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in conjunction with their partner Biogen’s quarterly report. In total, sales of JPY 10 billion were recorded in the quarter, an increase of approximately 60% compared to the previous quarter (Q2 2024: JPY 6.3 billion), resulting in a royalty to BioArctic amounting to approximately SEK 70 million.Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and

Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease

Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials in Alzheimer’s Disease (CTAD) congress in Madrid on October 29. Professor Lannfelt received the award in recognition for his pioneering work in Alzheimer's disease, specifically his scientific discoveries and contribution to drug development.Professor Lannfelt’s groundbreaking research has played a significant role in the

Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for Alzheimer's Disease Conference (CTAD) held in Madrid, Spain, and virtually from October 29 to November 1. Lars Lannfelt will be one of the keynote speakers at the conference. In addition, BioArctic’s partner Eisai present lecanemab data in two oral and one poster presentation at the meeting and three symposia will focus on lecanemab. Data shared will include the

Eisai will request reconsideration of initial decision for lecanemab in Australia

Stockholm, Sweden October 17, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia.Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab

BioArctic presents Nomination Committee

Stockholm, Sweden, October 11, 2024 – Pursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2024, as well as the Chairman of the Board (convener).September 30, 2024, the three largest shareholders were Demban AB, Ackelsta AB and The Fourth Swedish National Fund (Fjärde AP-fonden). The three

Number of shares and votes in BioArctic AB (publ) as of September 30, 2024

Stockholm, September 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during September issued 39,050 Class B shares for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 39,050 options of series 2019/2028.As of September 30, 2024, the last trading day of the month, the total number of shares in BioArctic AB amounts to 88,374,535 shares, of which 73,974,539 listed Class B shares and 14,399,996 unlisted Class A shares. The A

Interim Report for the period April – June 2024

Lecanemab authorised in Great Britain and EU re-examination in progress Events during the second quarter 2024 · BioArctic and Eisai entered into a research evaluation agreement regarding the drug candidate BAN2802 · Eisai received Fast Track designation and initiated a rolling Biologics License Application (BLA) to the FDA for subcutaneous maintenance dosing of Leqembi[®] · Eisai published sales projection for Leqembi for fiscal year 2024 (April 2024 – March 2025) of JPY 56.5 billion · The U.S. Food and Drug Administration (FDA) accepted Eisai’s Supplemental Biologics

Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Stockholm, August 27, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, while sparing the physiological form of the protein.In two separate phase 1 clinical studies conducted in collaboration with AbbVie, exidavnemab was tested on healthy volunteers to assess

Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain

Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)[1] heterozygotes or non-carriers.[2] Lecanemab becomes the first the medicine which targets an underlying cause of the disease, to be authorized in a

Regarding rumors of an imminent approval of lecanemab in Great Britain

Stockholm, Sweden August 22, 2024 – British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new information becomes available.--- The information was released for public disclosure, through the agency of the contact persons below, on August 22, 2024, at 08.34 a.m. CET.  For further information, please contact: Oskar Bosson, VP Communications

Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET

Stockholm, Sweden, August 15, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s second quarter report for April – June 2024 on Thursday, August 29, 2024, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on August 29, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the second quarter report, followed by a Q&A-session. If you wish to participate via webcast, please use the link below. Via the webcast you will be

Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates

Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi® (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.Leqembi’s approval in the UAE is based on the large global Phase 3 Clarity AD study. In

Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024

Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi[®] during the second quarter 2024, in conjunction with their partner Biogen’s second quarter report. In total, sales of JPY 6.3 billion were recorded in the period, an increase of more than 120% compared to the previous quarter (Q1 2024: JPY 2.8 billion), resulting in a royalty to BioArctic amounting to approximately SEK 43 million.Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and

Long-term lecanemab data show increased patient benefit with maintained safety profile

Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented the latest findings for lecanemab (generic name, brand name: Leqembi®). Three-year data show that lecanemab continues to give increased patient benefit for patients with early Alzheimer’s disease with maintained safety profile. In addition, data from the earliest patient cohort showed that 51% of these patients improved their cognition and function score after three years of treatment. The data was presented at the Alzheimer’s Association International Conference (AAIC) 2024, held

Eisai will seek re-examination of CHMP opinion för lecanemab

Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products for Human Use (CHMP’s) negative opinion posted today on the Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease in the EU.“We are surprised and very disappointed by the CHMP’s opinion posted today. Foremost  the negative opinion adopted by the CHMP is sad for all patients, caregivers and healthcare professionals in the EU who will now have to wait longer for a

CHMP has adopted a negative opinion on lecanemab for the EU

Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion on BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai’s Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease. BioArctic is currently consulting Eisai regarding forthcoming actions. A further update will be communicated later todayLecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, and Israel and is being marketed in

Long-term treatment data for lecanemab to be presented at AAIC 2024

Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will present the latest findings on lecanemab (generic name, brand name Leqembi®) at the Alzheimer’s Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Data presented will include three-year efficacy and safety data, as well as data supporting the importance of continued treatment of Alzheimer’s disease. In addition, BioArctic will present a poster on the Nordic Healthcare system’s readiness to

Leqembi approved for the treatment of Alzheimer’s disease in Israel

Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic name: lecanemab) has been approved for treatment of Alzheimer’s disease (AD) in Israel. Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Israel is the sixth territory to approve Leqembi following the US, Japan, China, South Korea and Hong Kong.Leqembi’s approval in Israel is based on the large global Phase 3

Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong

Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Department of Health in Hong Kong has approved Leqembi® (brand name in Hong Kong: “樂意保®”, generic name: lecanemab) for treatment of Alzheimer’s disease (AD). Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Hong Kong is the fifth approval following the US, Japan, China and South Korea.Leqembi’s approval in Hong Kong is based

Number of shares and votes in BioArctic AB (publ) as of June 28, 2024

Stockholm, June 28, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during June issued 12,800 Class B shares for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 12,800 options of series 2019/2028.As of June 28, 2024, the last trading day of the month, the total number of shares in BioArctic AB amounts to 88,335,485 shares, of which 73,935,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes

Leqembi[®] (lecanemab) launched in China

Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi[®] (brand name in China:  “乐意保[®]”, generic name: lecanemab) has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch Leqembi following the United States and Japan.Eisai estimates there are 17 million patients with MCI or mild dementia due to AD (collectively referred to as early AD) in China in 2024, which

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media